Related Experiment Video
Updated: Feb 3, 2026
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
[ADP-Induced Recalcified Blood Clotting Time as a Marker of Rethrombosis Risk and Effectiveness of Antiplatelet
L I Malinova1, N V Furman1, P V Dolotovskaya1
1Federal State Budgetary Institution, "Saratov Research Institute of Cardiology" at the RF Ministry of Health Care.
Insights
Adenosine diphosphate (ADP) induced blood-clotting time (BCT) is shorter in acute coronary syndrome (ACS) patients. This measurement may help predict ACS outcomes and evaluate antiplatelet therapy effectiveness.
Area of Science:
- Cardiology
- Hematology
- Clinical Medicine
Background:
- Acute coronary syndrome (ACS) poses significant cardiovascular risk.
- Effective antiplatelet therapy (APT) is crucial for managing ACS.
- Predictive markers for ACS prognosis and APT effectiveness are needed.
Purpose of the Study:
- To evaluate the utility of adenosine diphosphate (ADP) induced blood-clotting time (BCT) measurement.
- To assess ADP BCT for prognostication in acute coronary syndrome (ACS) patients.
- To determine ADP BCT's role in assessing antiplatelet therapy (APT) efficacy.
Main Methods:
- 163 male ACS patients and 38 healthy male volunteers were studied.
- ADP BCT was measured as the time to clot formation after ADP addition.
- Acetylsalicylic acid (ASA) effects on ADP BCT were assessed in volunteers.
- Cardiovascular risk was calculated using the GRACE score.
- Follow-up was 24 months with endpoints of cardiovascular death and rehospitalization.
Main Results:
- ACS patients exhibited significantly lower ADP BCT (134.8 sec) compared to healthy volunteers (85.7 sec) (p=0.015).
- Acetylsalicylic acid (ASA) significantly increased ADP BCT in healthy volunteers (p=0.041).
- ADP BCT showed a negative correlation with age in both groups (R=-0.431).
Conclusions:
- ADP induced blood-clotting time (BCT) is a potential biomarker in acute coronary syndrome (ACS).
- ADP BCT may aid in prognostication and monitoring antiplatelet therapy (APT) effectiveness.
- Further research is warranted to validate ADP BCT in clinical practice.
Purpose:
to assess the possibility of the use of ADP induced blood-clotting time measurement in clinical practice prognostication of the course of acute coronary syndrome (ACS) and assessment of effectiveness of antiplatelet therapy (APT).
Materials And Methods:
We enrolled in the study 163 male patients admitted to the coronary unit for acute coronary syndrome (ACS) and 38 male practically healthy volunteers (PHV). ADP induced blood-clotting time (ADP BCT) was measured as time (sec) between addition of ADP (10 μcmol) to recalcificated sample of citrate blood and clot formation. In healthy volunteers ADP BCT was determined before and 45 minutes after oral administration of acetylsalicylic acid (ASA, 250 mg). Risk of cardiovascular death was calculated using the GRACE score. Platelet function tests were performed by optical aggregometry. Follow-up period for patients with ACS was 24 months. The primary end point (PEP) was the composite of cardiovascular death and rehospitalization.
Results:
In ACS patients ADP BCT was significantly lower than in PHV: 134.8 (109.9; 161.3) vs 85.7 (60.5; 108.7) sec, p=0.015. In PHV ASA increased ADP BCT - 103.2 (95.1; 130.7) vs 133.1 (102.8; 154.3) sec, p=0.041. ADP BCT correlated with age in both PHV and patients (R= -0.431, p.
More Related Videos
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:26Acute Coronary Syndrome V: Nursing Management
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:42The ADP/ATP Carrier Protein